Wang Ying, Serfass Lucile, Roy Marie Odile, Wong Judy, Bonneau Anne Marie, Georges Elias
Institute of Parasitology, McGill University, Macdonald Campus, Ste-Anne de Bellevue, Que., Canada.
Biochem Biophys Res Commun. 2004 Feb 6;314(2):565-70. doi: 10.1016/j.bbrc.2003.12.117.
The use of anti-cancer chemotherapy often leads to the rise of multidrug-resistant (MDR) tumors. We have previously reported the overexpression of a 40kDa protein (P-40) in several MDR tumor cell lines. In this report we describe the cloning of a 1.4kb cDNA with an open reading frame of 344 amino acids that encodes the P-40 protein. Analysis of the P-40 amino acid sequence showed it is identical to the human annexin I (Anx-I) protein. The identity of the isolated P-40 cDNA as Anx-I was confirmed by the specific binding of IPM96 mAb to a 40kDa protein following the in vitro expression of P-40 full-length cDNA. Northern blot analysis of total RNA from drug-sensitive and -resistant cells revealed an increase in P-40 (or Anx-I) mRNA in drug-resistant cells relative to drug-sensitive cells. Transfection of Anx-I cDNA into drug-sensitive MCF-7 cells was carried out without further drug selection and showed 2- to 5-fold increase in resistance of transfected cells to adriamycin, melphalan, and etoposide. Conversely, transfection of reverse Anx-I cDNA into SKOV-3 cells decreased the expression of Anx-I without affecting the expression of other members of the annexin family and showed a 3- to 8-fold increase in sensitivity to these drugs. Of interest was the correlation between the presence of Anx-I and MDR in MDA-MB-231 cells when compared to MCF-7 cells. MDA-MB-231 cells show 3- to 20-fold increase in resistance to adriamycin, melphalan, and etoposide in the absence of detectable levels of P-glycoprotein (P-gp1), the multidrug resistance protein (MRP1) or the breast cancer resistance protein (BCRP). Taken together, these results provide the first direct evidence for the role of Anx-I in MDR of tumor cells.
抗癌化疗的使用常常导致多药耐药(MDR)肿瘤的产生。我们之前报道过一种40kDa蛋白(P-40)在多种MDR肿瘤细胞系中过表达。在本报告中,我们描述了一个1.4kb cDNA的克隆,其开放阅读框为344个氨基酸,编码P-40蛋白。对P-40氨基酸序列的分析表明,它与人类膜联蛋白I(Anx-I)蛋白相同。通过IPM96单克隆抗体与P-40全长cDNA体外表达后的一种40kDa蛋白的特异性结合,证实了分离出的P-40 cDNA为Anx-I。对药物敏感和耐药细胞的总RNA进行Northern印迹分析显示,相对于药物敏感细胞,耐药细胞中P-40(或Anx-I)mRNA增加。将Anx-I cDNA转染到药物敏感的MCF-7细胞中,无需进一步药物筛选,结果显示转染细胞对阿霉素、美法仑和依托泊苷的耐药性增加了2至5倍。相反,将反向Anx-I cDNA转染到SKOV-3细胞中可降低Anx-I的表达,而不影响膜联蛋白家族其他成员的表达,并且显示对这些药物的敏感性增加了3至8倍。有趣的是,与MCF-7细胞相比,MDA-MB-231细胞中Anx-I的存在与MDR之间的相关性。在未检测到P-糖蛋白(P-gp1)、多药耐药蛋白(MRP1)或乳腺癌耐药蛋白(BCRP)水平的情况下,MDA-MB-231细胞对阿霉素、美法仑和依托泊苷的耐药性增加了3至20倍。综上所述,这些结果为Anx-I在肿瘤细胞MDR中的作用提供了首个直接证据。